Improving persistence of CAR-T without preparative lymphodepletion

Advancing cancer treatments with Bio-Engine

Bio-Engine powers CAR-T engraftment
Bio-Engine is a new approach to power the engraftment of CAR-T without the need to prepare the patient with chemotherapy before their infusion. Our technology designs CAR-T to increase in numbers after infusion driven by the ability to be boosted by normal blood cells. Avoidance of preparative chemotherapy facilitates repeated infusions of CAR-T to improve their therapeutic potential and to reduce the costs and complexity of clinical care.

Learn more about Bio-Engine

View Video
Bio4t2 LinkedIn
Bio4t2TM, PrismCoreTM, Bio-EngineTM and Bio-StrikeTM are trademarks of Bio4t2. Privacy Page »